Phibro Animal Health (NASDAQ:PAHC) Stock Rating Lowered by StockNews.com

Phibro Animal Health (NASDAQ:PAHC) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a research note issued on Thursday.

Other equities research analysts also recently issued research reports about the company. Roth Mkm reaffirmed a “buy” rating and issued a $21.00 target price on shares of Phibro Animal Health in a research report on Tuesday, August 29th. Morgan Stanley decreased their target price on Phibro Animal Health from $17.00 to $16.00 and set an “equal weight” rating for the company in a research report on Thursday.

Phibro Animal Health Price Performance

PAHC stock opened at $9.66 on Thursday. The stock has a 50-day moving average price of $12.20 and a two-hundred day moving average price of $13.60. Phibro Animal Health has a 12-month low of $9.59 and a 12-month high of $16.52. The company has a current ratio of 3.33, a quick ratio of 1.75 and a debt-to-equity ratio of 1.60. The company has a market cap of $391.23 million, a PE ratio of 18.94, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68.

Phibro Animal Health (NASDAQ:PAHC) last posted its quarterly earnings results on Thursday, August 31st. The company reported $0.38 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.40 by ($0.02). Phibro Animal Health had a net margin of 2.12% and a return on equity of 16.84%. The firm had revenue of $255.00 million for the quarter, compared to analysts’ expectations of $256.68 million. During the same period last year, the firm posted $0.36 EPS. As a group, research analysts predict that Phibro Animal Health will post 1.18 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Rhumbline Advisers boosted its holdings in Phibro Animal Health by 3.4% in the third quarter. Rhumbline Advisers now owns 77,171 shares of the company’s stock valued at $985,000 after purchasing an additional 2,506 shares during the last quarter. UBS Group AG boosted its holdings in Phibro Animal Health by 46.7% in the third quarter. UBS Group AG now owns 44,096 shares of the company’s stock valued at $563,000 after purchasing an additional 14,047 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Phibro Animal Health by 1.0% in the third quarter. Charles Schwab Investment Management Inc. now owns 237,354 shares of the company’s stock valued at $3,031,000 after purchasing an additional 2,319 shares during the last quarter. Madison Wealth Management purchased a new position in Phibro Animal Health in the third quarter valued at about $204,000. Finally, New York State Common Retirement Fund boosted its holdings in Phibro Animal Health by 20.9% in the third quarter. New York State Common Retirement Fund now owns 69,944 shares of the company’s stock valued at $893,000 after purchasing an additional 12,110 shares during the last quarter. Hedge funds and other institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.